Search Results - "JÄNNE, Pasi A"

Kinase drug discovery 20 years after imatinib: progress and future directions by Cohen, Philip, Cross, Darren, Jänne, Pasi A.

“…Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or mutations in their genes, cause cancer and other diseases…”
Get full text

Kinase drug discovery 20 years after imatinib by Cohen, Philip, Cross, Darren, Jänne, Pasi A

Get full text

The quest to overcome resistance to EGFR-targeted therapies in cancer by Chong, Curtis R, Jänne, Pasi A

“…Despite the initial promise of cancer therapies targeted against the epidermal growth factor receptor (EGFR), tumors treated with these agents eventually…”
Get full text

Overcoming therapy resistance in EGFR-mutant lung cancer by Passaro, Antonio, Jänne, Pasi A, Mok, Tony, Peters, Solange

“…Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth…”
Get full text

False positive plasma genotyping due to clonal hematopoiesis by Hu, Yuebi, Ulrich, Bryan, Supplee, Julianna, Kuang, Yanan, Lizotte, Patrick H, Feeney, Nora, Guibert, Nicolas, Awad, Mark M, Wong, Kwok-Kin, Janne, Pasi A, Paweletz, Cloud Peter, Oxnard, Geoffrey R

“…Plasma cell-free DNA (cfDNA) genotyping is increasingly used in cancer care, but assay accuracy is debated. Because most cfDNA is derived from peripheral blood…”
Get full text

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions by Haikala, Heidi M, Jänne, Pasi A

“…HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years…”
Get full text

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer by Engelman, Jeffrey A., Jänne, Pasi A.

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non–small cell lung cancer patients…”
Get full text

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies by Passaro, Antonio, Jänne, Pasi A, Peters, Solange

“…Antibody-drug conjugates (ADCs) are one of the fastest-growing oncology therapeutics, merging the cytotoxic effect of conjugated payload with the high specific…”
Get full text

The biology and treatment of EML4-ALK non-small cell lung cancer by Sasaki, Takaaki, Rodig, Scott J, Chirieac, Lucian R, Jänne, Pasi A

“…Abstract The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a…”
Get full text

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer by Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

“…Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety…”
Get full text

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer by Li, Bob T, Smit, Egbert F, Goto, Yasushi, Nakagawa, Kazuhiko, Udagawa, Hibiki, Mazières, Julien, Nagasaka, Misako, Bazhenova, Lyudmila, Saltos, Andreas N, Felip, Enriqueta, Pacheco, Jose M, Pérol, Maurice, Paz-Ares, Luis, Saxena, Kapil, Shiga, Ryota, Cheng, Yingkai, Acharyya, Suddhasatta, Vitazka, Patrik, Shahidi, Javad, Planchard, David, Jänne, Pasi A

“…A multicenter phase 2 study looked at the capacity of the antibody–drug conjugate trastuzumab deruxtecan to induce responses in HER2 -mutant lung cancer. The…”
Get full text

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M by Thress, Kenneth S, Paweletz, Cloud P, Felip, Enriqueta, Cho, Byoung Chul, Stetson, Daniel, Dougherty, Brian, Lai, Zhongwu, Markovets, Aleksandra, Vivancos, Ana, Kuang, Yanan, Ercan, Dalia, Matthews, Sarah E, Cantarini, Mireille, Barrett, J Carl, Jänne, Pasi A, Oxnard, Geoffrey R

“…A mutation conferring resistance to novel irreversible EGFR inhibitors is identified in cell-free plasma DNA from lung cancer patients. Here we studied…”
Get full text

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK) by Powell, Chelsea E, Gao, Yang, Tan, Li, Donovan, Katherine A, Nowak, Radosław P, Loehr, Amanda, Bahcall, Magda, Fischer, Eric S, Jänne, Pasi A, George, Rani E, Gray, Nathanael S

“…We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung…”
Get full text

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling by Engelman, Jeffrey A, Zejnullahu, Kreshnik, Mitsudomi, Tetsuya, Song, Youngchul, Hyland, Courtney, Park, Joon Oh, Lindeman, Neal, Gale, Christopher-Michael, Zhao, Xiaojun, Christensen, James, Kosaka, Takayuki, Holmes, Alison J, Rogers, Andrew M, Cappuzzo, Federico, Mok, Tony, Lee, Charles, Johnson, Bruce E, Cantley, Lewis C, Jänne, Pasi A

“…The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations,…”
Get full text

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA by OXNARD, Geoffrey R, PAWELETZ, Cloud P, JÄNNE, Pasi A, YANAN KUANG, MACH, Stacy L, O'CONNELL, Allison, MESSINEO, Melissa M, LUKE, Jason J, BUTANEY, Mohit, KIRSCHMEIER, Paul, JACKMAN, David M

“…Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow noninvasive assessment of tumor biology, yet many existing assays are cumbersome…”
Get full text

TGFβ pathway inhibition in the treatment of non-small cell lung cancer by Eser, Pınar Ö., Jänne, Pasi A.

“…Advanced non-small cell lung cancer (NSCLC) continues to be an incurable family of thoracic malignancies that is chronically managed with chemotherapy,…”
Get full text

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer by Oxnard, Geoffrey R, Thress, Kenneth S, Alden, Ryan S, Lawrance, Rachael, Paweletz, Cloud P, Cantarini, Mireille, Yang, James Chih-Hsin, Barrett, J Carl, Jänne, Pasi A

“…Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by…”
Get full text

Top advances of the year: Targeted therapy for lung cancer by Makarem, Maisam, Jänne, Pasi A.

“…The past year has offered significant advancements in the field of non–small cell lung cancer (NSCLC), both in the early and advanced disease settings. The…”
Get full text

Lung cancer in patients who have never smoked — an emerging disease by LoPiccolo, Jaclyn, Gusev, Alexander, Christiani, David C., Jänne, Pasi A.

“…Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-related lung cancers continue to account for the majority of…”
Get full text

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS by Ambrogio, Chiara, Köhler, Jens, Zhou, Zhi-Wei, Wang, Haiyun, Paranal, Raymond, Li, Jiaqi, Capelletti, Marzia, Caffarra, Cristina, Li, Shuai, Lv, Qi, Gondi, Sudershan, Hunter, John C., Lu, Jia, Chiarle, Roberto, Santamaría, David, Westover, Kenneth D., Jänne, Pasi A.

“…The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD),…”
Get full text